Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune Thrombocytopenia
Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune Thrombocytopenia
SEATTLE–(BUSINESS WIRE)–Cyrus Biotech today announced that its protease CYR212 has been selected as its clinical candidate for chronic IgG-driven autoimmune diseases.